Rerun: Lars Fruergaard Jørgensen CEO of Novo Nordisk
In Good Company with Nicolai Tangen
Innovations and Challenges in Obesity Treatment
This chapter explores the advances in obesity treatment through a novel GLP-1 medication developed by a long-established diabetes-focused pharmaceutical company. It addresses the complexities of ensuring accessibility and affordability for patients in different economic regions, particularly in the U.S. versus Europe, and highlights the financial motivations driving innovation in healthcare. The conversation underscores the importance of maintaining medical oversight and addressing regulatory challenges to enhance patient access to innovative treatments.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
